³§³Ü³¾³¾²¹°ù²â:​â¶Ä‹ ÌìÃÀӰԺ’s cell line development Lightning technology genetically engineers high-expressing, highly stable production cell lines. This standardized, scalable platform for protein manufacturing offers consistent performance from laboratory to GMP-scale bioreactors and enables rapid scale-up. The technology is a proven approach to generate cell lines across a variety of protein types, from standard monoclonal antibodies (mAbs) to next-generation biologics, including bispecific and multi-specific antibodies, multi-gene, and other complex molecules. This executive summary addresses the growing challenge for biologics manufacturers to create effective cell line development technologies that ensure stable, high-titer expression across various protein formats, along with the solutions provided by ÌìÃÀÓ°Ôº for our customers.

Summary: Webcast presentation specifically designed for pharmaceutical & biotech consultants and early stage development partners. Hear three early drug development industry experts present their insights and techniques to help your clients get their molecules from preclinical to Phase 1 studies.

Learn strategies for fund raising, assembling early-phase IND’s, and hear real life case studies on CMC content, characterization and formulation. Give your clients solutions for success! Give your clients solutions for success!​